CHD1 and ovarian carcinoma: For example, miR-144-3p that targets ARID1A promotes sunitinib resistance in clear cell renal cell carcinoma [94]; miR-30a-5p that directly targets CHD1 enhances cisplatin sensitivity of ovarian cancer cells through the Wnt/β-catenin pathway [172], whereas lncRNAs uc.57* is involved in BCL11A regulation and thus promotes tamoxifen resistance in breast cancer [129].